The value of pharma schemes rose as investors shifted focus to drugmakers, considered defensive in uncertain times. As per data from Value Research the mid-cap category offered the highest return of 8.93%, followed by multi-caps which returned 7.88%.
How SIP has been the strong hero across historical market cycles
Market downturns create buying opportunities through SIPs as they lower your average cost and enhance returns during recovery. Long-term investments in small and midcaps can
April 5, 2025